4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-16-000084
$BHCCIK 0000885590operating
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 6:28 PM ET
Size
5.9 KB
Accession
0000885590-16-000084
Insider Transaction Report
Form 4
Schiller Howard Bradley
EVP and CFO
Transactions
- Award
Common Stock, no par value
2015-07-01+1,506→ 590,875 total
Footnotes (3)
- [F1]Prorated annual grant of restricted Share Units equal $343,750 divided by the closing price of registrant common stock on the date of grant.
- [F2]This number includes the maximum number of Common Shares that may be delivered in settlement of performance-based Restricted Share Units ("PSUs") that were previously reported on Form 4 in Table II. See note (3).
- [F3]The initial grant of PSUs was reported to vest based on total shareholder return ("TSR") between a price of $136.41 starting on December 1, 2014 and the average stock price for the 20 trading days starting on each measurement dates: 25% would vest on September 1, 2017, 50% on December 1, 2017 and 25% on March 1, 2018, (or 25% on September 1, 2018, 50% on December 1, 2018 and 25% on March 1, 2019, if applicable). Unit vesting is contingent on TSR performance between 10% and 30% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs remain unvested for all 300,000 Common Shares.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 6:28 PM ET
- Size
- 5.9 KB